Unique activities of cholecystokinin-58; Physiological and pathological relevance

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 15, Issue 1, 2008, Pages 48-53

  Green, Gary M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Acute pancreatitis; Cholecystokinin; Exocrine pancreatic secretion; Gastrointestinal hormones

Indexed keywords

CHLORIDE; CHOLECYSTOKININ; CHOLECYSTOKININ 58; CHOLECYSTOKININ OCTAPEPTIDE; UNCLASSIFIED DRUG; WATER;

ACUTE PANCREATITIS; AMINO ACID SEQUENCE; BRAIN; HORMONE ACTION; HUMAN; PANCREAS SECRETION; PROTEIN FUNCTION; REVIEW; SEQUENCE ANALYSIS; SMALL INTESTINE;

ACUTE DISEASE; ANIMALS; CHLORIDES; CHOLECYSTOKININ; GASTROINTESTINAL TRACT; HUMANS; PANCREAS; PANCREATIC JUICE; PANCREATITIS; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; WATER;

EID: 38049098442     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e3282f3d92b     Document Type: Review

References (37)

1. Johnson LR. Peptides of the gastrointestinal tract. In: Gastrointestinal physiology. Amsterdam: Elsevier; 2007. pp. 1-12. This paper is a recent review (Chapter 1 of monograph) of the discovery, chemistry, distribution and release of gastrointestinal peptides, and their role in regulation of the functions of the gastrointestinal tract.
2. Harper AA, Raper HS. Pancreozymin, a stimulant of the secretion of pancreatic enzymes in extracts of the small intestine. J Physiol 1943; 102:115-125.
3. Mutt V, Jorpes JE. Structure of porcine cholecystokinin-pancreozymin. Eur J Biochem 1968; 6:156-162.
4. Oates PS, Bruce NW, Morgan RG. Pancreatic blood flow in the rat during enlargement, involution, and cholecystokinin treatment. Am J Physiol Gastrointest Liver Physiol 1984; 247:G457-G462.
5. Okabayashi Y, Otsuki M, Baba S. Cholecystokinin in the entero-insular axis. Diabetes Res Clin Pract 1989; 7 (Suppl 1):S79-S85.
6. Hardikar AA, Wang XY, Williams LJ, et al. Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. Endocrinology 2002; 143:3505-3514.
7. Baum F, Nauck MA, Ebert R, et al. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist. Digestion 1992; 53:189-199.
8. Rehfeld JF, Friis-Hansen L, Goetze JP, et al. The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 2007; 7:1154-1165. This is a recent, authoritative review of the biology of the CCK/gastrin family of peptides.
9. Reeve JR Jr, Eysselein VE, Rosenquist G, et al. Evidence that CCK-58 has structure that influences its biological activity. Am J Physiol Gastrointest Liver Physiol 1996; 270:G860-G868.
10. Eberlein GA, Eysselein VE, Hesse WH, et al. Detection of cholecystokinin-58 in human blood by inhibition of degradation. Am J Physiol 1987; 253:G477-G482.
11. Eysselein VE, Eberlein GA, Schaeffer M, et al. Characterization of the major form of cholecystokinin in human intestine: CCK-58. Am J Physiol 1990; 258:G253-G260.
12. Hoffmann P, Eberlein GA, Reeve JR Jr, et al. Comparison of clearance and metabolism of infused cholecystokinins 8 and 58 in dogs. Gastroenterology 1993; 105:1732-1736.
13. Reeve JR Jr, Green GM, Chew P, et al. CCK-58 is the only detectable endocrine form of cholecystokinin in rat. Am J Physiol Gastrointest Liver Physiol 2003; 285:G255-G265.
14. Reeve JR Jr, Wu SV, Keire DA, et al. Differential bile-pancreatic secretory effects of CCK-58 and CCK-8. Am J Physiol Gastrointest Liver Physiol 2004; 286:G395-G402.
15. Eysselein VE, Bottcher W, Kauffman GL Jr, et al. Molecular heterogeneity of canine cholecystokinin in portal and peripheral plasma. Regul Pept 1984; 9:173-185.
16. Reeve JR, McVey DC, Bunnett NW, et al. Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58. Pancreas 2002; 25:50-55.
17. Reeve JR Jr, Rosenquist GL, Keire DA, et al. Crucial role of position 40 for interactions of CCK-58 revealed by sequence of cat CCK-58. Biochem Biophys Res Commun 2006; 348:819-825. This critically important study showed that a single amino acid change in the N-terminal sequence of CCK58 had a marked effect on the immunoreactivity of the C-terminal active fragment, probably by its effect on the tertiary structure of the C-terminal active fragment.
18. Reeve JR Jr, Liddle RA, Shively JE, et al. Sequence variation outside the "active" region of dog and rabbit cholecystokinin-58 results in bioactivity differences. Pancreas 2006; 32:306-313. The results of this study of receptor binding, receptor activation and immunological properties are the first direct demonstration that amino acids outside the C-terminal active fragment influence CCK biological activity.
19. Keire DA, Solomon TE, Reeve JR Jr. Identical primary sequence but different conformations of the bioactive regions of canine CCK-8 and CCK-58. Biochem Biophys Res Commun 1999; 266:400-404.
20. Keire DA, Solomon TE, Reeve JR Jr. NMR evidence for different conformations of the bioactive region of rat CCK-8 and CCK-58. Biochem Biophys Res Commun 2002; 293:1014-1020.
21. Johnson LR. Pancreatic secretion. In: Gastrointestinal Physiology. Amsterdam: Elsevier; 2007. pp. 85-95. A review (Chapter 9 of monograph) describes the elements of the two-component paradigm for regulation of pancreatic secretion.
22. Yamamoto M, Reeve JR Jr, Keire DA, et al. Water and enzyme secretion are tightly coupled in pancreatic secretion stimulated by food or CCK-58 but not by CCK-8. Am J Physiol Gastrointest Liver Physiol 2005; 288:G866-G879. This study is the first demonstration that synthetic cholecystokinin-58 manifests a physiological action that is absent from all other forms of CCK. This paper also challenges the long-standing two-component paradigm of pancreatic exocrine secretion.
23. Green GM, Taguchi S, Friestman J, et al. Plasma secretin, CCK, and pancreatic secretion in response to dietary fat in the rat. Am J Physiol 1989; 256:G1016-G1021.
24. Bolender RP. Stereological analysis of the guinea pig pancreas. I. Analytical model and quantitative description of nonstimulated pancreatic exocrine cells. J Cell Biol 1974; 61:269-287.
25. nd ed. New York, NY: Raven Press, Ltd; 1993. pp. 501-526.
26. Grady T, Mah'Moud M, Otani T, et al. Zymogen proteolysis within the pancreatic acinar cell is associated with cellular injury. Am J Physiol Gastrointest Liver Physiol 1998; 275:G1010-G1017.
27. Saluja AK, Lerch MM, Phillips PA, et al. Why does pancreatic overstimulation cause pancreatitis? Annu Rev Physiol 2007; 69:249-269. This recent authoritative review focuses on the phenomenon of acute pancreatitis caused by supramaximal doses of pancreatic secretagogues in animal models.
28. Yamamoto M, Reeve JR Jr, Green GM. Supramaximal CCK-58 does not induce pancreatitis in the rat: role of pancreatic water secretion. Am J Physiol Gastrointest Liver Physiol 2007; 292:G964-G974. This recent study showed that under conditions in which CCK8 caused severe edematous pancreatitis, CCK58 induced little or no pancreatic damage, and this was associated with maintenance of pancreatic water secretion by CCK58 but not by CCK8. This research builds on the preceding study [22] that showed that enzyme and water secretion are tightly coupled in CCK58-stimulated pancreatic secretion.
29. Taguchi S, Green GM, Sasaki K, et al. A study of pancreatic exocrine secretion with bombesin in conscious rats. Showa Univ J Med Sci 1995; 7:143-150.
30. Ji B, Bi Y, Simeone D, et al. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology 2001; 121: 1380-1390.
31. Miyasaka K, Shinozaki H, Jimi A, et al. Amylase secretion from dispersed human pancreatic acini: neither cholecystokinin a nor cholecystokinin B receptors mediate amylase secretion in vitro. Pancreas 2002; 25:161-165.
32. Murphy JA, Criddle DN, Sherwood M, et al. Human pancreatic acinar cells have functional cholecystokinin receptors [abstract]. Pancreas 2006; 33:485.
33. Fuxe K, Agnati LF, Vanderhaeghen JJ, et al. Cholecystokinin neuron systems and their interactions with the presynaptic features of the dopamine neuron systems. A morphometric and neurochemical analysis involving studies on the action of cholecystokinin-8 and cholecystokinin-58. Ann N Y Acad Sci 1985; 448:231-254.
34. Bonetto V, Jornvall H, Andersson M, et al. Isolation and characterization of sulphated and nonsulphated forms of cholecystokinin-58 and their action on gallbladder contraction. Eur J Biochem 1999; 264:336-340.
35. Tatemoto K, Jornvall H, Siimesmaa S, et al. Isolation and characterization of cholecystokinin-58 [CCK-58] from porcine brain. FEBS Lett 1984; 174: 289-293.
36. Kreis ME, Zittel TT, Raybould HE, et al. Prolonged intestinal afferent nerve discharge in response to cholecystokinin-58 compared to cholecystokinin-8 in rats. Neurosci Lett 1997; 230:89-92.
37. Raboin SJ, Reeve JR Jr, Green GM, et al. Differential effects of exogenous CCK-8 and CCK-58 on food intake [abstract]. Appetite 2007; 49:322.